After undergoing surgery or chemotherapy, breast cancer patients are often asked to continue taking a drug called tamoxifen (triamcinolone acetonide) to prevent recurrence. However, due to the side effects of this drug, many patients often do not follow the doctor’s instructions, unauthorized discontinuation of the drug. A new British study shows that stopping the drug will increase the risk of cancer recurrence and death. Postoperative adjuvant endocrine therapy for breast cancer is suitable for patients with hormone receptor ER and/or PR-positive breast cancer, with the aim of reducing the rate of tumor recurrence and improving the overall survival rate. For premenopausal patients, tamoxifen is generally preferred (pay attention to check the endometrial thickness during treatment), 20 mg/d, for 5-10 years, and it is also feasible to replace tamoxifen with toremifene in our country. For postmenopausal patients, it is recommended to use the third-generation aromatase inhibitor (pay attention to detect the bone density), and tamoxifen can be used in addition, and toremifene can also be used. Endocrine therapy is an effective method of breast cancer treatment, the efficacy of which is certain, and must be used well and sufficiently, and do not stop the drug without authorization! Some new patients heard that the side effects of triamcinolone acetonide will be how to be scared not to eat, do not realize the seriousness of the consequences of stopping the drug. Because of their own ignorance to stop the drug relapse that is not responsible for their own.